CD43 or leukosialin is a transmembrane sialoglycoprotein, whose extracellular domain participates in cell adhesiveness and the cytoplasmic tail regulates a variety of intracellular signal transduction pathways involved in cell proliferation. CD43 is abundantly expressed on the surface of hematopoietic cells, but CD43 expression is also frequently found in the tumor cells of nonhematopoietic origin. In the early stages of some tumors, the accumulation of tumor suppressor protein p53 has been described. Here, we show that the expression of CD43 causes the induction of functionally active p53 protein.
Introduction
CD43, also known as sialophorin or leukosialin, is a common transmembrane sialylated glycoprotein expressed on the surface of most hematopoietic cells (Andersson and Gahmberg, 1978; Remold-O'Donnell et al., 1984; Carlsson and Fukuda, 1986) . CD43 is important for the function of the immune system and appears to be involved in cell adhesion and cell proliferation. Owing to the structural characteristics of the extracellular domain of CD43, this molecule has both adhesive and antiadhesive properties (Ardman et al., 1992; Ostberg et al., 1996) . Although there are no ligands known for the extracellular domain of CD43, ligation of CD43 causes cell signaling probably via the cytoplasmic tail of CD43. Such signaling has been shown to involve the mitogen-activated protein kinase (MAPK) pathway and leads to interleukin-2 gene expression (Pedraza-Alva et al., 1998) . CD43-mediated signals also induce the activation of AP-1, NF-AT and NF-kB transcription factors in human T-lymphocytes, probably as a result of protein kinase C involvement (Santana et al., 2000) .
The effects and signaling of CD43 has mainly been studied in leukocyte-type cell lines, where it has been shown to be involved in T-cell proliferation (Mentzer et al., 1987; Axelsson et al., 1988; Park et al., 1991) . In the B-cell lineage, CD43 is present on the cell surface of terminally differentiated cells causing prolonged survival, but not in less-differentiated cells (Dragone et al., 1995; Rosenstein et al., 1999) . The reason for CD43 not being studied in other cell types is that CD43 has long been considered as an exclusive leukocyte marker. However, Baeckstrom et al. (1995) first found CD43 in a colon cancer cell line and later Sikut et al. (1997) reported that the expression of CD43 is frequent in colon adenomas and carcinomas, where it occurs in the early stages of tumor development. Normal colon epithelial cells do not express detectable levels of CD43. The high frequency of CD43 expression already in the early stages of tumor (adenoma) could suggest an important role of this protein in tumor development (Sikut et al., 1997) . CD43 is also expressed in other nonhematopoietic tumor cells, but not in cells of the premalignant lesions adjacent to the neoplastic tissues (Santamaria et al., 1996) . CD43 expression is also frequent in established human cell lines of different origins (Fernandez-Rodriguez et al., 2002) . One reason for CD43 being unnoticed outside of the hematopoietic lineage is that CD43 is differently glycosylated in other cells, as, for example, the human colon adenocarcinoma COLO205 cells (Baeckstrom et al., 1991) . Moreover, in colon adenoma and carcinoma tissues, CD43 seems to have a more intracellular localization, in contrast to the membrane localization typical for leukocyte-type cells (Sikut et al., 1999) .
p53 is considered to be one of the most important tumor suppressor genes. The p53 gene has been shown to be lost or contain inactivating mutations in about half of human cancers from different tissues (Ko and Prives, 1996; Levine, 1997) . The product of this gene is a transcription factor that plays an important role in the maintenance of genomic stability in response to a number of cellular stress signals including DNA-damage and activated cellular oncogenes (reviewed in Giaccia and Kastan, 1998). The activation of p53 leads to the accumulation of this protein in the nucleus, where it can activate its target genes mediating the function of p53 as the 'guardian of the genome'. One of the first identified and probably most studied targets of p53 is the p21 WAF1/cip1 cyclin-dependent kinase inhibitor, which mediates the p53-induced G1 arrest checkpoint (ElDeiry et al., 1993; Harper et al., 1993) . Another important p53 target gene is Mdm2, the role of which is to maintain the p53 protein at a low level in normal conditions and terminate the p53 response after stress stimulus has been eliminated (Lane and Hall, 1997 , and references therein).
Tumor suppressor protein ARF (p19 ARF in mouse and p14 ARF in human cells) is encoded by partially overlapping alternative reading frame at the p16 INK4A locus. p19 ARF is required for the accumulation of p53 in response to hyperproliferative signals from oncogenic Ras, Myc, E1A and E2F-1 (Bates et al., 1998a; de Stanchina et al., 1998; Palmero et al., 1998; Zindy et al., 1998) . p19
ARF interacts with Mdm2 and prevents the Mdm2-induced p53 degradation (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) .
The accumulation of p53 protein has been shown in early stages of different tumors including colon adenomas, but p53 mutations occur relatively late during colorectal carcinogenesis (Fearon and Vogelstein, 1990; Mazars et al., 1991) . As the expression of CD43 in colon adenomas was also an early event (Sikut et al., 1997) , it was considered of interest to determine if there was a relation between the CD43 presence and the p53-response pathway in early tumor development. In this paper, we can show that the overexpression of CD43 causes an accumulation of p53 in the cell. The p53 protein induced by CD43 is transcriptionally active, stimulating transcription from p53-responsive promoters. CD43 does not induce p53 in cells lacking ARF, but ARF expression in these cells restores the ability of CD43 to induce p53, resulting in cell suicide. Thus, the p53 response could be activated by the possible mitogenic stimuli caused by CD43 expression.
Results

CD43 overexpression increases the level of p53 protein
To examine the possible relationship between CD43 and p53, we created a model system that could depict the regulation of p53 protein during early carcinogenesis in the presence of excess CD43. p53-null mouse cell line 10(1) was transiently transfected with either human p53 expression plasmid alone or together with a CD43 expression plasmid. Cells were harvested 15 h after transfection followed by Western blot analysis with p53-specific antibodies. The results presented in Figure 1a show that the level of p53 protein is significantly higher in cells cotransfected with CD43 (lane 3). To avoid artifacts caused by overexpression, the GAPDH protein was expressed in the cells. The expression of this irrelevant protein does not increase the level of p53 (Figure 1a , lane 4) nor does transfection with an empty plasmid (pcDNA3.1, lane 1). Two CD43 deletion mutants were used, one D1-125CD43 lacking the first 125 amino acids of CD43 fused to a signal sequence and a fusion protein of EGFP at the Nterminal end of the cytoplasmic domain of CD43 (EGFP-CD43ct). None of these increased the level of p53, instead this was lowered (Figure 1b, lanes 4 and 5) . The overexpression of CD43 itself did not affect the levels of irrelevant protein (GAPDH, data not shown). These results confirm that the elevation of p53 protein levels is CD43 specific and that it is only the full-length CD43 that is responsible for the described phenomenon.
CD43 increases the stability of p53 protein
Further, we tested the possibility that signaling by CD43 could affect the mRNA level of p53. The result of the Northern blot analysis (Figure 2) showed that the p53 mRNA levels remained the same under conditions of CD43 overexpression. Thus, CD43 causes the elevation of the p53 protein level probably in the course of translation or afterwards.
The p53 protein level in the cell is determined by the rates of its synthesis and degradation. p53 has a short half-life of only about 10 min in normal (nontransformed) cells (Reich et al., 1983; Rogel et al., 1985) due to a rapid degradation (Kubbutat and Vousden, 1998) . In response to a wide range of cellular stress factors, the half-life of p53 protein can increase rapidly. The question thus arose whether CD43 could affect the turnover of p53 protein. We transfected 10(1) cells with CD43 activates p53 and ARF L Kadaja et al p53 expression vector alone or together with CD43, or b-catenin expression vectors were followed by the pulsechase experiment. The transfection with b-catenin was used as a positive control, while its overexpression can cause the accumulation of functionally competent p53 (Damalas et al., 1999) . Based on the data shown in Figure 3 , we can say that the half-life of p53 is significantly longer after the cotransfection of cells with CD43 or b-catenin ( Figure 3b ) than with p53 alone (Figure 3a ). Post-translational modifications, including phosphorylations, are believed to play a role in stabilizing p53 protein. Phosphorylation at Ser15 has been reported to impair the ability of Mdm2 to bind p53 (reviewed in Giaccia and Kastan, 1998) . With the stimulation of CD43, in addition to the increase in the total p53 protein level, there was also a clear increase in the phosphorylation of p53 at Ser15 (Figure 3c , lane 3), showing that accumulated p53 is phosphorylated at this site. Together, these results prove that CD43 prolongs the p53 protein half-life, probably due to the interference in the p53-Mdm2 interaction preventing thus the degradation of the p53 protein.
p53 protein induced by CD43 is transcriptionally active
It was essential to determine whether the p53 accumulated due to CD43 overexpression was transcriptionally active. To investigate the ability of p53 to stimulate transcription from p53-responsive promoters, 10(1) cells were transfected with plasmids containing chloramphenicol acetyl transferase (CAT) gene under the control of p53-specific promoters and plasmids expressing p53 and CD43. The Mdm2 promoter was activated several fold by cotransfection with CD43 as compared to p53 alone ( Figure 4a ). Similar effect was observed with the p21 promoter ( Figure 4b ). In both cases, CD43 alone was not able to activate p53-responsive promoters. Next, we tested whether p53 is able to induce transcription also from the endogenous p53-responsive chromosomal genes. The levels of Mdm2, p53 and p21 proteins were detected in 10(1) cells expressing p53 alone or together with CD43 or GAPDH. CD43 caused the elevation of Mdm2 and p21 protein levels, whereas the irrelevant protein GAPDH did not ( Figure 5 , lanes 3 and 4, respectively). These results show that p53 induced by CD43 is transcriptionally active.
Ability of CD43 to induce p53 depends on the presence of the ARF protein The experiments described above were performed in 10(1) cells using exogenous p53. To determine whether endogenous p53 is similarly modulated by CD43, several Figure 2 CD43 does not affect the level of p53 mRNA. The 10(1) cells were transfected with 500 ng of human p53 expression plasmid and 10 mg CD43 expression plasmid. As a negative control, parallel transfection with empty plasmid was carried out. RNA was analysed 15 h after transfection by Northern blotting to detect p53 mRNA. The same blot was subsequently reprobed for b-actin to normalize the data. The results from two separate experiments were quantified and expressed as a bar graph CD43 activates p53 and ARF L Kadaja et al p53-positive cell lines were analysed such as the mouse embryo fibroblast cell line NIH3T3, the human colon carcinoma cell line LoVo and the human mammary gland adenocarcinoma cell line MCF-7, but no effect of CD43 on p53 was detected (data not shown). None of these cell lines express tumor suppressor protein ARF, which is induced by oncogenic activation upstream p53 and prevents Mdm2-mediated degradation of p53 (Bates et al., 1998b; Stott et al., 1998) . We hypothesized that the activation of p53 by CD43 could be an oncogenic stimulus to the cells, and addressed whether the ARF protein is upregulated in 10(1) cells by CD43. Indeed, the expression of CD43 in 10(1) cells resulted in the increase of endogenous ARF (Figure 6a , lane 2). It has been previously shown that b-catenin increases the p19ARF protein levels both in wild-type (wt) and p53-null mouse embryo fibroblasts (Damalas et al., 2001) . Consistent with this, ARF expression was induced by bcatenin in 10(1) cells (Figure 6a, lane 3) . Negative controls empty pcDNA3.1 and GAPDH, had no effect (Figure 6a, lanes 1 and 4) . Next, we transfected ARFnull mouse embryonic fibroblasts (MEFs) with p19ARF expression plasmid either alone or together with the vector expressing CD43 or EGFP. The expression of p53 and p19ARF proteins was examined by Western blotting with p53-and p19ARF-specific antibodies.
According to the results of the other groups, there was a slight increase in the levels of p53 protein in ARFexpressing cells (Figure 6b ). CD43 was not able to induce endogenous p53 without ARF (Figure 6b , lane 4), but ARF expression in these cells restored the ability of CD43 to induce p53 ( Figure 6b , lane 2). The irrelevant protein EGFP did not induce neither ARF nor p53 protein (Figure 6b, lane 3) . We also created a derivative cell line from MCF7, where CD43 overexpression is induced only after tetracycline addition into the culture medium. These cells were transfected with p14ARF expression plasmid and the level of the p53 protein was analysed by flow cytometry. As shown in Figure 6c , CD43 induces the elevation of the endogenous p53 protein when p14ARF is present (Figure 6c , lower right), whereas without ARF this was not the case (Figure 6c, upper right) , suggesting that the mechanism may be the same in both mouse and human cells. The expression of the CD43 protein is indicated on the left.
CD43 overexpression induces apoptosis in ARF-null MEFs
Having determined a link between p53-dependent signaling and CD43, we were interested in the biological outcome of CD43 overexpression in our experimental system after the activation of the p53 protein. Several groups have reported that p53 triggers apoptosis in response to oncogenic overexpression depending on ARF protein (reviewed in Lowe and Sherr, 2003) , which is important for tumor suppression. We therefore studied whether the overexpression of CD43 could lead to an apoptotic response. ARF-null MEFs were transfected with an empty pcDNA3.1 vector and with vectors expressing wt CD43, b-catenin, the cytoplasmic domain of CD43 (EGFP-CD43ct) and EGFP either alone or together with p19ARF expression plasmid. At 48 h after transfection, cells were stained with Annexin V-PE and apoptotic cells were counted by flow cytometry. The rate of apoptosis remained quite low without the expression of ARF in these cells (Figure 7 , white bars), but with p19ARF expression, there was a slight increase in apoptotic signal in the case of negative controls, that is, EGFP-CD43ct, EGFP and the empty vector control (Figure 7 , black bars). CD43 expression caused a considerable increase in apoptotic cell counts when cotransfected with p19ARF, as did b-catenin, which was used as a positive control. CD43 also suppressed drastically colony-forming ability of ARFnull MEFs, if coexpressed with ARF protein compared to the expression of CD43 alone (data not shown).
Taken together, these data demonstrate that CD43 overexpression leads to ARF activation and apoptotic response, and support the idea that CD43 can activate the ARF/p53 growth control pathway in response to possible mitogenic stimuli.
Discussion
Human tumors develop mainly due to the sustained activation of oncogenes and loss of function of tumor suppressor genes. Cells protect themselves from deregulated cell growth through compensatory mechanisms that arrest cell growth or induce cell suicide. Tumor suppressor p53 plays a central role in response to cell stress signals, activating other genes that mediate the cellular activities needed to induce cell cycle arrest and/ or apoptosis (see, for review, Sherr, 1996; Weinberg, 1997) .
In the present study, we have shown that the overexpression of CD43 induces the accumulation of p53 protein. This provides the first evidence that CD43, expressed in colon adenomas and carcinomas but not in normal colon epithelial cells, can trigger the activation of p53 protein.
Investigating this phenomenon, we have shown that the effect of CD43 on p53 is not at the level of mRNA transcription, but is likely to be translational or posttranslational. In normal cells, p53 protein is kept at low levels due to its rapid degradation by proteosome machinery. Using the pulse-chase method, we showed that the half-life of p53 is significantly longer after cotransfection with CD43. In response to cellular stress, besides the stabilization of the p53 protein, it is activated for transcription presumably via phosphorylations, acetylations or other modifications. Multiple protein kinases are capable of phosphorylating distinct sites on the p53 protein (reviewed in Giaccia and Kastan, 1998; Meek, 1998; Prives and Hall, 1999) . The phosphorylation of the Ser15 site of the p53 protein has been attributed to have a physiological role in the regulation of p53 activity. It is believed that Ser15 is one of the sites on p53, whose modification interferes the Mdm2-p53 binding. We show here that accumulated p53 induced by CD43 is phosphorylated at Ser15, suggesting that in our case p53 is stabilized through the disruption of binding with Mdm2.
Among of other kinases Erk, a member of MAPK, has been shown to mediate the phosphorylation of p53 at Ser15, which in turn activates the transactivation function of p53 protein (Persons et al., 2000; Wang and Shi, 2001 ). CD43 has been reported to induce cell proliferation through the activation of Syk-dependent Erk signaling (Miura et al., 2001) , suggesting that Erk could be one of the possibilities to link CD43-dependent signal transduction pathway to p53. Our experiments showed that p53 induced by CD43 is able to induce the transcription from both artificial p53-specific promoter constructs and cellular response genes. Namely, Mdm2 and p21, one of the most important p53 response genes, were upregulated under the conditions of CD43 overexpression, supporting the idea that in addition to p53 functionality CD43 triggers the p53-dependent cellular response to possible mitogenic stimuli. As several other kinases can induce p53 Ser15 phosphorylation, there should be more upstream mediators of p53 to mediate signaling in response to CD43 overexpression. We have also no data at present as to how else p53 could be modified under these conditions.
Immortalized cell lines and cancer cells tend to have defects in cell cycle checkpoints. The deregulated expression of oncogenes is often the cause of cell transformation. It is important to note that, in contrast to immortalized cell lines, the overexpression of an oncoprotein in primary cells or in vivo results in either cell cycle arrest or even induces cell death. This has inspired the model of tumorigenesis as a multistep process, which first overcomes the primary safeguard against cellular transformation through additional changes, mainly inactivating the tumor suppressor genes. An important factor besides p53 in keeping cell growth under control is ARF protein (Sherr and Weber, 2000) . Previous reports have indicated that several oncogenes such as Myc, Ras and E1A induce the activation of p53 through tumor suppressor ARF (de Stanchina et al., 1998; Palmero et al., 1998; Zindy et al., 1998) . As CD43 expression led to an increase in the level of endogenous ARF protein in 10(1) cells, it is clear that in our case p53 activation operates via ARF tumor suppressor protein. The main role of ARF activation is the stabilization of p53 by Mdm2 inhibition and activation of p53-dependent growth suppression. If cells lack ARF, they fail to inhibit oncogene-induced hyperproliferation. The reintroduction of ARF into these cells restores their ability to respond to oncogenic stimuli . CD43 was unable to induce p53 in cells lacking endogenous ARF, such as NIH3T3, MCF-7 and LoVo. The coexpression of CD43 and ARF proteins in ARF-null mouse embryo fibroblasts and MCF-7 cells resulted in the elevation of the endogenous p53 protein level. Moreover, CD43 induced apoptosis if coexpressed with ARF in ARF-null MEFs. These results confirm that aberrant CD43 expression in colon epithelial cells could represent an oncogenic stimulus leading to the uncontrolled cell division, resulting in tumor development through the disruption of ARF/p53 tumor suppressor pathway.
Different molecular events contribute to the development and progression of carcinomas. What kind of mechanism could be responsible for tumor development in the case of CD43? CD43-mediated signals have been attributed an important role in the regulation of gene expression and cell function. A serine/threonine kinase has been cloned that can specifically interact with the cytoplasmic domain of CD43. As this kinase localizes both in cytoplasm and in the nucleus, it is believed that CD43 may mediate its biologic effects through the activation of a kinase cascade, resulting in the expression of specific genes and cell growth (Wang et al., 2000) . Signal transduction mediated by CD43 has been shown to involve an MAPK pathway (Axelsson et al., 1988; Santana et al., 2000) . As mentioned above, adhesion via CD43 induces tyrosine kinase Syk activation (Miura et al., 2001) . Syk activity in turn is a key regulator of Akt kinase activity and is also shown to induce downstream activation of ERK and JNK kinases (reviewed in Stewart and Pietenpol, 2001 ). All these molecules are known to be involved in signal transduction processes in the cell and are therefore attractive candidates linking CD43-mediated signaling to the p53-response pathway (Figure 8 ).
In summary, CD43 overexpression can lead to the activation of survival signal transduction pathways that stimulate cell growth and the activation of p53 in response to these proliferative abnormalities provides a strong protection against malignant growth bringing cells to die. We have established a relation between CD43 and p53 pathways. The exact mechanism of CD43 in triggering p53 response remains to be elucidated and will be of interest for further studies.
Materials and methods
Cells and transfection
The 10(1) cells (p53-null mouse embryo fibroblasts) and ARFnull MEFs were cultured at 5% CO 2 and 371C in DMEM (Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS) (Gibco Life Technologies) and penicillin/streptomycin (both 100 U/ml). Transfections were performed using the electroporation method as described earlier (Joers et al., To regulate CD43 expression in the mammary gland adenocarcinoma cell line MCF-7, a tetracycline-inducible expression system T-Rex was used (Invitrogen). The full-length cDNA of human CD43 was cloned to the pcDNA4/TO vector. To generate MCF-7/TR cell line, the cells were transfected with pcDNA6/TR regulatory plasmid and stable clones selected using 10 mg/ml Blasticidin (Invitrogen). The selected clones were transfected with pcDNA4/TO/CD43 expression vector and selected using 50 mg/ml Zeocin (Invitrogen). The CD43 overexpression was induced by tetracycline (0.75 mg/ml) for 42 h. Transfections with pCG-p14ARF plasmid were mediated by the liposome reagent DMRIE-C according to the manufacturer's protocol (Invitrogen) and the cells were analysed 42 h after transfection.
Plasmid constructs and antibodies p53, GAPDH, p19ARF and p14ARF cDNAs were cloned into pCG vector (Tanaka and Herr, 1990) . Human b-catenin expression vector pCI-neo-b-catenin encodes mutated bcatenin (S33Y). Human CD43 cDNA was expressed in pcDNA3.1Zeo vector. The plasmids containing CAT gene were as follows: pBP100-CAT contains the p53-binding site from the Mdm2 gene (Wu et al., 1993) . In pWWP-CAT, the CAT gene is under the control of the p21/Waf1 promoter (El-Deiry et al., 1993) . The primary antibodies used were: anti-p53 (pAb421, pAb240 and DO-1, Eurogenetics, anti-phospho Ser15, Abcam Ltd), anti-Mdm2 (2A10, Eurogenetics), anti-p19ARF (R562, Abcam Ltd), anti-p21 WAF1/Cip1 (F-5, Santa Cruz Biotechnology) and anti-actin (C-4, Boehringer Mannheim). The secondary antibodies used were: biotinylated sheep anti-mouse and biotinylated donkey anti-rabbit (Amersham) and HRPconjugated goat anti-mouse IgG (LabAS Ltd, Estonia).
Protein analysis
For immunoblots, cells were lysed on ice for 1 h in lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 8), 1% Triton X-100, supplemented with the complete protease inhibitor mixture (Roche, Boehringer Mannheim). Protein concentration in supernatants was estimated by using Bradford reagent (Sigma). Equal amounts of protein from each lysate were analysed by SDS-PAGE gels and transferred to a PVDF membrane. Western blot assays were performed in accordance with standard procedures by using ECL detection (Amersham). For flow cytometry analysis, approximately 10 6 cells were washed with PBS, fixed in methanol at À201C for 15 min and permeabilized in 0.1 % saponin solution on ice for 30 min. The anti-CD43 antibody 4D2 (Sikut et al., 1999) was added to the cells followed by incubation on ice for 45 min. Biotinconjugated goat anti-mouse secondary antibody (Dako) was used, diluted 1 : 200 and incubated on ice for 45 min followed by streptavidin-APC substrate (Perkin-Elmer). Finally, the cells were incubated with Alexa488-conjugated anti-p53 antibody DO-1 on ice for 45 min. The cells were analysed with a FACSCalibur cell sorter and CellQUEST Pro program (BD Immunocytometry systems).
Northern blot
Total RNA was isolated from cells using the Quiagen RNeasy kit according to the manufacturer's protocol. Equal amounts of RNA (10 mg/lane) were separated in 1% agarose-formaldehyde gel and transferred overnight onto Hybond nylon membrane (Amersham). Probes were labeled with [a-32 P]dCTP using decalabel kit (Fermentas). The probes were detected and quantified using a Phosphoimager s scanner and Image QuaNT s software (Molecular Dynamics).
Immunoprecipitation and pulse chase
Cells were methionine/cysteine starved for 1 h and pulselabeled with [
35 S]methionine and cysteine (Redivue Promix, Amersham Biosciences) and then chased with cold media for an indicated time. The cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8), 1% Triton X-100) supplemented with protease inhibitors. p53 protein was immunoprecipitated from supernatants by p53-specific antibodies, conjugated to Dynabeads M-450 precoated with goat anti-mouse IgG secondary antibodies (Dynal ASA, Oslo, Norway). Immunoprecipitates were subjected to SDS-PAGE and labeled proteins were subjected to imaging using Phosphoimager 
CAT assay
The 10(1) cells were transfected with 1 mg reporter plasmid with 10 ng pCG-p53 and 5 mg pcDNA3.1-CD43. Cellular extracts were prepared 15 h after transfection using 0.25 M Tris-HCl (pH 7.8) with three freeze-thaw cycles. The supernatants were subjected to CAT assay as described earlier (Sambrook et al., 1989) . The signal was detected using a Phosphoimager s scanner (Molecular Dynamics) and the relative CAT activity was calculated using Image QuaNT s software.
Apoptosis assay
Cells were collected and stained with Annexin V-PE according to the manufacturer's protocol (BD Biosciences). The cells were analysed with a FACSCalibur cell sorter and CellQUEST Pro program (BD Immunocytometry systems).
